伊立替康联合国产替吉奥胶囊治疗转移性结直肠癌的临床研究  

Clinical research on Irinotecan combined with domestic Gimeracil and Oteracil Potassium Capsules for patients with metastatic colorectal cancer

作　　者：吕美玲[1] 李卫敏[1] 李雨遥[1] 王丽娜[1] 罗长琴[1] 周小娟[1] 杨谨[1] 

机构地区：[1]西安交通大学医学院第一附属医院肿瘤内科,陕西西安710061

出　　处：《现代肿瘤医学》2013年第8期1818-1821,共4页Journal of Modern Oncology

摘　　要：目的:观察伊立替康联合国产替吉奥胶囊作为一线方案治疗转移性结直肠癌的临床疗效和安全性。方法:24例既往未化疗的转移性结直肠癌患者,应用伊立替康联合国产替吉奥胶囊化疗,伊立替康(180mg/m2)第1天,国产替吉奥胶囊口服剂量(60mg/m2,2次/日),连续14天,21天为1周期,连用2周期以上评价疗效。结果:24例疗效均可评价,其中CR 0例,PR 15例,SD 3例,PD 6例,RR 62.5%,DCR 75.0%,15例缓解的病例,中位缓解时间为1.8个月,中位疾病进展时间为5.6个月,中位无进展生存期为13个月。不良反应主要为Ⅰ-Ⅱ级,表现为白细胞减少、血小板减少、疲乏、恶心、呕吐等。结论:伊立替康联合国产替吉奥胶囊治疗转移性结直肠癌疗效确切、耐受性好、易于实施,值得临床进一步推行。Objective：To investigate the efficacy and safety of combining irinotecan with domestic Gimeracil and Oteracil Potassium Capsules as first-line treatment in patients with metastatic colorectal cancer（mCRC）.Methods：All 24 patients with previously untreated mCRC received domestic Gimeracil and Oteracil Potassium Capsules combined irinotecan as first-line treatment.Irinotecan 180mg/m2 ivgtt d1,Gimeracil and Oteracil Potassium Capsules 60mg/m2 bid po d1-14,21 days as one cycle.Therapeutic efficacy was evaluated every two cycles.Results：All cases were evaluated.No patient achieved complete remission,15 cases partial response,3 cases stable disease and 6 cases progressive disease.The response rate was 62.5%,the disease control rate was 75%.For the 15 response cases,the median response time was 1.8 months,the median time to progression（TTP） was 5.6 months,the median progression-free survival（PFS） was 13 months.The side-effect was grade I-II,including leukocytopenia,thrombocytopenia,fatigue,nausea and vomiting.Conclusion：Combining Irinotecan with domestic Gmeracil and Oteracil Potassium Capsules as first-line treatment is an effective,well tolerated and convenient regimen in mCRC patients,which deserved further study.

关 键 词：替吉奥胶囊 伊立替康 转移性结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]